We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

166 hedge funds and large institutions have $372M invested in Verve Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

36% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 47

17% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 30

2% more funds holding

Funds holding: 163 → 166 (+3)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6.97% less ownership

Funds ownership: 97.62% → 90.65% (-7%)

43% less call options, than puts

Call options by funds: $576K | Put options by funds: $1M

66% less capital invested

Capital invested by funds: $1.08B → $372M (-$712M)

Holders
166
Holders Change
+3
Holders Change %
+1.84%
% of All Funds
2.4%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
35
Increased
64
Reduced
47
Closed
30
Calls
$576K
Puts
$1M
Net Calls
-$428K
Net Calls Change
+$670K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$20.5M
2
BlackRock
BlackRock
New York
+$7.84M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$5.69M
4
VPC
Vestal Point Capital
New York
+$3.14M
5
Goldman Sachs
Goldman Sachs
New York
+$2.87M

Top Sellers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
-$19.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$15.1M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.3M
4
State Street
State Street
Massachusetts
-$11M
5
NAMA
Nikko Asset Management Americas
New York
-$9.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$2.96M +$2.27M +361,891 +147%
PAI
27
Palo Alto Investors
California
$2.81M – – –
Northern Trust
28
Northern Trust
Illinois
$2.79M -$53.8K -8,559 -1%
TI
29
Trexquant Investment
Connecticut
$2.55M +$2.27M +360,630 +222%
Citadel Advisors
30
Citadel Advisors
Florida
$2.48M -$4.21M -669,725 -57%
VPC
31
Vestal Point Capital
New York
$2.44M +$3.14M +500,000 New
Renaissance Technologies
32
Renaissance Technologies
New York
$2.32M +$1.73M +275,173 +138%
Bank of America
33
Bank of America
North Carolina
$2.31M +$627K +99,792 +27%
Charles Schwab
34
Charles Schwab
California
$2.18M -$257K -40,944 -8%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$2.13M -$346K -55,003 -11%
CSS
36
Cubist Systematic Strategies
Connecticut
$1.93M +$1.77M +281,173 +246%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.81M +$743K +118,266 +47%
CAM
38
Cormorant Asset Management
Massachusetts
$1.71M – – –
PP
39
PDT Partners
New York
$1.63M +$900K +143,256 +75%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$1.34M +$314K +49,922 +22%
Jane Street
41
Jane Street
New York
$1.24M +$1.42M +226,657 +835%
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$1.18M +$1.52M +242,468 New
Two Sigma Advisers
43
Two Sigma Advisers
New York
$1.16M +$1.27M +202,000 +550%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$1.1M -$1.55M -247,235 -52%
GCP
45
GSA Capital Partners
United Kingdom
$994K +$1.28M +203,677 New
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$939K +$879K +139,882 +266%
Ameriprise
47
Ameriprise
Minnesota
$876K +$499K +79,458 +79%
Mirae Asset Global ETFs Holdings
48
Mirae Asset Global ETFs Holdings
Hong Kong
$702K +$905K +144,027 New
GCM
49
Graham Capital Management
Connecticut
$695K +$716K +113,872 +398%
AG
50
Algert Global
California
$671K +$864K +137,496 New
1
2
3 4 5

VERV Hedge Fund Activity: Q2 2024 in Review

166 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2024, worth a combined $372M — down 66% from $1.08B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new VERV positions and 30 closed out — a net gain of 5 holders — while 64 added to existing stakes and 47 trimmed.

The largest buyer was Millennium Management, adding an estimated $20.5M. The largest seller was ARK Investment Management, cutting an estimated $19.5M.

  • 166 institutional investors held Verve Therapeutics (VERV) as of Q2 2024, up from 163 in Q1 2024.
  • Funds reported $372M of Verve Therapeutics stock for Q2 2024, down 66% quarter-over-quarter.
  • 35 funds opened new Verve Therapeutics positions in Q2 2024 and 30 closed out, a net change of +5 holders.
  • The largest Verve Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $20.5M added.
  • The largest Verve Therapeutics seller in Q2 2024 was ARK Investment Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q2 2024.